Clinical trial
MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary…
NCT00298467 · Bristol-Myers Squibb, Industry · Withdrawn
Key facts
| NCT number | NCT00298467 |
|---|---|
| Title | MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma |
| Official title | An Open-label, Fixed-dose, Multicenter, Phase II Study of MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Large-Cell |
| Intervention type | Drug |
| Interventions | MDX-060 |
| Enrollment | 45 |
| Start date | Feb 1, 2006 |
| First posted | Mar 2, 2006 |
| Last update posted | Apr 26, 2010 |
| Countries | France, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: